At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCT Nuvectis Pharma, Inc.
Post-Market Trading 11-22 19:06:15 EST
5.10
+0.20
+4.08%
盘后5.09
-0.01-0.20%
18:32 EST
High5.14
Low4.61
Vol170.11K
Open4.94
D1 Closing4.90
Amplitude10.80%
Mkt Cap95.13M
Tradable Cap33.49M
Total Shares18.65M
T/O830.71K
T/O Rate2.59%
Tradable Shares6.57M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Nuvectis Pharma reports data from Phase 1b study of NXP800
BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer
Nuvectis Pharma Reports Encouraging Nxp800 Interim Data Supporting Ongoing Enrollment in Phase 1B Study in Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.